Department of Oral and Maxillofacial Surgery, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
Department of Oral and Maxillofacial Surgery, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
Surgery. 2022 Sep;172(3):1007-1014. doi: 10.1016/j.surg.2022.04.054. Epub 2022 Jun 29.
Blood clot formation or hemostasis is vital to minimize blood loss and mitigate the risk of death from severe bleeding. This study investigates the characteristics of a novel hemostatic composite containing chemically modified chitosan and starch for emergency bleeding control. The performance of this novel hemostatic powder was compared with commercially available starch-based (Arista AH) and chitosan-based (Celox) hemostats.
Hemostatic composite was prepared according to the patent registered by the authors (Patent No. 100865, Iranian Intellectual Property Organization) in Bani Zist Baspar Healda, Inc. (Shiraz, Iran). The properties of the product were surveyed by Fourier-transform infrared spectroscopy and compared with Arista-AH and Celox as commercial counterparts. The cytocompatibility, hemolysis, platelet and red blood cells (RBCs) adhesion, biocompatibility, and biodegradability attributes were evaluated in in vivo and in vitro studies. Hemostatic efficacy was evaluated in 24 healthy 6-month-old male New Zealand white rabbits in lethal and sublethal injuries of femoral artery and veins, respectively.
Modification and composition led to a fundamental development in physicochemical characteristics including swelling properties, water absorption, and platelet and RBC adhesion due to improved electrostatic and hydrophilic attributes. The significant superiority in clotting efficiency was confirmed after the application of the composite in 2 models of venous and arterial injury in comparison with common commercial hemostats.
Simultaneous use of water-absorbing compounds and introducing positively charged functional groups to hemostatic material led to a considerable control of femoral bleeding in emergency conditions. The introduced composite was biodegradable and biocompatible and prompts RBC aggregation and platelet adhesion.
血栓形成或止血对于最大限度地减少失血和降低严重出血导致死亡的风险至关重要。本研究调查了一种新型止血复合材料的特性，该复合材料含有化学改性壳聚糖和淀粉，用于紧急止血控制。将这种新型止血粉末的性能与市售的基于淀粉的（Arista AH）和基于壳聚糖的（Celox）止血剂进行了比较。
止血复合材料根据作者（伊朗知识产权组织专利号 100865）在 Bani Zist Baspar Healda，Inc.（伊朗设拉子）注册的专利制备。通过傅里叶变换红外光谱法对产品的性能进行了调查，并与 Arista-AH 和 Celox 作为商业对照进行了比较。在体内和体外研究中评估了细胞相容性、溶血、血小板和红细胞（RBC）黏附、生物相容性和生物降解性特性。在 24 只健康的 6 月龄雄性新西兰白兔的股动脉和股静脉致死性和亚致死性损伤中，评估了止血效果。
修饰和组成导致理化特性发生了根本变化，包括由于静电和亲水性属性的提高而导致的溶胀特性、吸水性以及血小板和 RBC 黏附性。与普通商业止血剂相比，在静脉和动脉损伤的 2 种模型中应用复合材料后，证实了在凝血效率方面的显著优势。
同时使用吸水化合物并向止血材料中引入带正电荷的官能团，可以在紧急情况下对股部出血进行有效的控制。所引入的复合材料具有生物降解性和生物相容性，可促进 RBC 聚集和血小板黏附。
